Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)
Public ClinicalTrials.gov record NCT01926782. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients With Primary Hypercholesterolemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To determine the efficacy, long-term safety, and tolerability of alirocumab 300 mg every 4 weeks (Q4W), in comparison with placebo, as well as its potential as a starting regimen. The dose regimen of 75 mg every 2 weeks (Q2W), as used in other studies, was added as a calibrator.
Study identification
- NCT ID
- NCT01926782
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 803 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2013 (Type not available)
- Primary completion
- Sep 2014 (Actual)
- Completion
- Apr 2015 (Actual)
- Last update posted
- Mar 21, 2017
2013 – 2015
United States locations
- U.S. sites
- 49
- U.S. states
- 27
- U.S. cities
- 49
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Chandler | Arizona | — | — |
| Not listed | Goodyear | Arizona | — | — |
| Not listed | Carmichael | California | — | — |
| Not listed | Fresno | California | — | — |
| Not listed | West Hills | California | — | — |
| Not listed | Wildomar | California | — | — |
| Not listed | Colorado Springs | Colorado | — | — |
| Not listed | Golden | Colorado | — | — |
| Not listed | Boynton Beach | Florida | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | Safety Harbor | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Boise | Idaho | — | — |
| Not listed | Meridian | Idaho | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Gurnee | Illinois | — | — |
| Not listed | Evansville | Indiana | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Not listed | Iowa City | Iowa | — | — |
| Not listed | Kansas City | Kansas | — | — |
| Not listed | Louisville | Kentucky | — | — |
| Not listed | Monroe | Louisiana | — | — |
| Not listed | Auburn | Maine | — | — |
| Not listed | Methuen | Massachusetts | — | — |
| Not listed | Minneapolis | Minnesota | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Rochester | New York | — | — |
| Not listed | Farmville | North Carolina | — | — |
| Not listed | Greensboro | North Carolina | — | — |
| Not listed | Greenville | North Carolina | — | — |
| Not listed | Raleigh | North Carolina | — | — |
| Not listed | Wilson | North Carolina | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Marion | Ohio | — | — |
| Not listed | Tulsa | Oklahoma | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Wyomissing | Pennsylvania | — | — |
| Not listed | Knoxville | Tennessee | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Orem | Utah | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | South Jordan | Utah | — | — |
| Not listed | Norfolk | Virginia | — | — |
| Not listed | Richmond | Virginia | — | — |
| Not listed | Spokane | Washington | — | — |
| Not listed | Tacoma | Washington | — | — |
| Not listed | Kenosha | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01926782, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 21, 2017 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01926782 live on ClinicalTrials.gov.